Expertise in
8
conditions

Dr. Vilmarie M. Rodriguez

General Practice
Bayamon, PR 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
8
conditions
Bayamon, PR 

Overview

Vilmarie Rodriguez is a primary care provider, practicing in General Practice in Bayamon, Puerto Rico.

Dr. Rodriguez is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Mesenteric Venous Thrombosis, Acute Lymphoblastic Leukemia (ALL), Venous Thromboembolism (VTE), May Thurner Syndrome, and Thrombectomy.

She is actively involved in clinical research, co-authoring 127 peer reviewed articles and participating in 12 clinical trials. Dr. Rodriguez is currently accepting new patients.

Specialties

General Practice

Licenses

General Practice in PR

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cooperativa de Seguros de Vida de Puerto Rico
  • INSURANCE PLAN
First Medical Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Innovacare
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
  • OTHER MEDICARE PART D
Mapfre Insurance
  • INSURANCE PLAN
  • MEDICARE MAPD
Medical Card System
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
  • PPO
MMM Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Plan De Salud Menonita
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
View 4 Less Insurance Carriers -

Locations

Bayamon, PR 00956

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
Childhood Cancer Survivor Study
Childhood Cancer Survivor Study
Enrollment Status: Recruiting
Publish Date: June 17, 2026
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Enrollment Status: Completed
Publish Date: July 31, 2026
Intervention Type: Drug, Behavioral, Other, Procedure
Study Drug: 6-Mercaptopurine
Study Phase: Phase 3
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Biological, Radiation
Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine
Study Phase: Phase 2
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Enrollment Status: Active_not_recruiting
Publish Date: July 29, 2026
Intervention Type: Drug, Procedure, Biological, Other, Radiation
Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Enrollment Status: Completed
Publish Date: May 28, 2026
Intervention Type: Other, Drug
Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
Enrollment Status: Completed
Publish Date: February 27, 2025
Intervention Type: Procedure, Drug
Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 2
View 8 Less Clinical Trials

127 Total Publications

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.
Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma.
Journal: medRxiv : the preprint server for health sciences
Published: April 10, 2026
Similar Doctors
Expertise in
2
conditions
Dr. Fernando J. Bravo
General Practice
Expertise in
2
conditions
Dr. Fernando J. Bravo
General Practice

Emergency Physician Providers LLC

Arecibo, PR 
 (35.9 miles away)
787-436-0727
Experience:
9+ years
Languages Spoken:
English

Fernando Bravo is a primary care provider, practicing in General Practice in Arecibo, Puerto Rico. He has been practicing medicine for over 9 years. Dr. Bravo is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Genital Herpes, Oral Herpes, and Cytomegalovirus Infection.

Expertise in
5
conditions
Dr. Francisco M. Ojeda
General Practice
Expertise in
5
conditions
Dr. Francisco M. Ojeda
General Practice
664 Calle Un Apt 604, 
San Juan, PR 
 (10.9 miles away)
787-381-8034
Languages Spoken:
English
See accepted insurances

Francisco Ojeda is a primary care provider, practicing in General Practice in San Juan, Puerto Rico. Dr. Ojeda is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Heart Attack, Coronary Heart Disease, Acute Coronary Syndrome, Heart Failure, and Transcatheter Aortic Valve Replacement (TAVR).

Expertise in
19
conditions
Dr. Luis E. Rodriguez
General Practice
Expertise in
19
conditions
Dr. Luis E. Rodriguez
General Practice
Before you request
Guaynabo, PR 
 (5.2 miles away)
787-810-7242
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Luis Rodriguez is a primary care provider, practicing in General Practice in Guaynabo, Puerto Rico. Dr. Rodriguez is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Urinary Incontinence, Familial Dilated Cardiomyopathy, High Cholesterol, and Hypertensive Heart Disease. Dr. Rodriguez is currently accepting new patients.

Frequently Asked Questions about Dr. Vilmarie M. Rodriguez

How do I make an appointment with Dr. Vilmarie M. Rodriguez?

You can book an appointment with Dr. Vilmarie M. Rodriguez by calling their office at 787-730-3446. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Vilmarie M. Rodriguez a top-rated expert for Mesenteric Venous Thrombosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Vilmarie M. Rodriguez is classified as an Advanced expert for Mesenteric Venous Thrombosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Vilmarie M. Rodriguez specialize in?

While Dr. Vilmarie M. Rodriguez is a General Practice, they have specific expertise in Mesenteric Venous Thrombosis, Acute Lymphoblastic Leukemia (ALL), and Venous Thromboembolism (VTE). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within General Practice.

Does Dr. Vilmarie M. Rodriguez participate in research or clinical trials?

Yes. Dr. Vilmarie M. Rodriguez has published 127 articles and abstracts on conditions like Mesenteric Venous Thrombosis. You can view a list of Dr. Vilmarie M. Rodriguez's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Vilmarie M. Rodriguez accept my insurance?

Dr. Vilmarie M. Rodriguez accepts most major insurance plans, including Blue Cross Blue Shield and Cooperativa de Seguros de Vida de Puerto Rico. We recommend calling the office directly at 787-730-3446 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rodriguez's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 49 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile